Taking stock of the drug industry, from the lab to the medicine chestMarch 14, 2023Check out STAT+Sponsored ByBy Ed SilvermanPharmalot Columnist, Senior Writer Alex Hogan/STAT STAT+ | Democratic lawmakers press pharmacy chains on abortion pill access Pharmacies are in "a little bit of a damned if you do, damned if you don't situation" said Greer Donley, a University of Pittsburgh professor By Ed Silverman STAT+ | Novo Nordisk to lower insulin prices by up to 75% amid growing pressure The move comes after Eli Lilly recently announced plans to lower list prices for its most commonly prescribed insulin products by 70%. By Ed Silverman STAT+ | PhRMA chief dings health insurers over drug prices at their own conference PhRMA's Steve Ubl used an in-person health insurance industry conference to blame insurers for making people pay too much for drugs. By John Wilkerson Molly Ferguson/STAT STAT+ | Amylyx's ALS drug launch starts strong. That could be trouble for the FDA The FDA could face a quandary if an ongoing and larger clinical trial shows ALS patients aren't benefiting from the drug. By Adam Feuerstein Introducing the 2023 STATUS List, the definitive accounting of leaders in the life sciences The 2023 STATUS List recognizes standout individuals in health, medicine, and the life sciences whose work has advanced those fields. By STAT Staff More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments